Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
19 evidence topics · 15 sources
Lesion growth: pooled rate across natural history studies
“The pooled mean GA growth rate was 1.66 mm2/year (SD = 1.27 mm2/year, I2 = 97.0%, p < 0.001) from 23 studies (3,078 patients) reported with growth rate in mm2/year and 0.33 mm/year (SD = 0.17 mm/year, I2 = 83.0%, p < 0.001) from 12 studies (1,808 patients) reported with growth rate in mm/year. Larger mean baseline GA area in mm2 was associated with larger mean growth rate in both mm2/year and mm/year (p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lesion growth: constant radial enlargement in untreated eyes
“We included 25 studies with data from 2942 eyes. The RLM yielded the best goodness of fit and predictive performance of GA progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The GA radius enlarged at a constant rate of 0.163 mm/year (95% confidence interval, 0.158-0.167 mm/year), which was independent of time (r = -0.108). The RLM predicted the mean age of onset of GA as 67.4±5.2 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lesion growth: AREDS2 cohort
“In the prevalence cohort, the change over time in square root of GA area was 0.29 mm/year (95% CI 0.27–0.30), i.e. 0.17 disc diameters/year, or (without square root transformation) 1.42 mm2/year (1.33–1.52), i.e. 0.61 disc areas/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GA enlargement was significantly faster for non-central than for central GA at 0.31 mm/year (0.30–0.33) and 0.22 mm/year (0.20–0.24), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lesion growth: AREDS cohort
“Median initial lesion size was 4.3 mm2. Average change in digital area of GA from baseline was 2.03 mm2 (standard error of the mean, 0.24 mm2) at 1 year, 3.78 mm2 (0.24 mm2) at 2 years, 5.93 mm2 (0.34 mm2) at 3 years, and 1.78 mm2 (0.086 mm2) per year overall.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lesion growth: prospective single-center natural history study
“The median overall enlargement rate was 2.1 mm2/year (mean, 2.6 mm2/year). Eyes with larger areas of atrophy at baseline tended to have larger enlargement rates, but knowledge of prior rates of enlargement was the most significant factor in predicting subsequent enlargement rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lesion growth and visual acuity loss over 24 months in the Proxima A and B studies
“At 24 months, adjusted mean (standard error) change in GA lesion area from baseline was 3.87 (0.15) mm2 in participants with bilateral GA (Proxima A), 3.55 (0.16) mm2 in the fellow eye CNV cohort (Proxima B), and 2.96 (0.25) mm2 in the fellow eye intermediate AMD cohort (Proxima B).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjusted mean (standard error) changes in BCVA and LLVA (ETDRS letters) in the study eye from baseline to 24 months were -13.88 (1.40) and -7.64 (1.20) in Proxima A, -9.49 (1.29) and -7.57 (1.26) in Proxima B fellow eye CNV cohort, and -11.48 (3.39) and -8.37 (3.02) in Proxima B fellow eye intermediate AMD cohort, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Foveal progression: time from noncentral to central geographic atrophy in AREDS
“Median time to developing central GA after any GA diagnosis was 2.5 years (95% confidence interval, 2.0-3.0). Average visual acuity decreased by 3.7 letters at first documentation of central GA, and by 22 letters at year 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Foveal progression: 2-year and 4-year rates in AREDS2
“For the 628 participants (and 734 eyes) whose incident GA was non-central GA at its first appearance, mean follow-up time was 4.7 years (SD 0.8; IQR 0.7). The Kaplan-Meier plot for the progression from non-central to central GA in these eyes is shown in Figure 5, with a 32% 2-year rate and a 57% 4-year rate of progression to central GA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Foveal progression: 5-year change in a U.S. population-based cohort
“Of 53 eyes with multiple visits, the overall increase in atrophy was 6.4 mm2 over a 5-year period. The atrophy progressed to involve the foveal center in 47% of eyes and there was a mean decrease of 17 letters read correctly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Foveal progression and visual acuity change over 24 months in the IRIS Registry
“In total, 69 441 patients were included: 44 120 (64%) GA:GA and 25 321 (36%) GA:nAMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both GA:GA and GA:nAMD cohorts, nonsubfoveal study eyes had better mean (standard deviation) VA at index (67 [19.3] and 66 [20.3] letters) than subfoveal eyes (59 [23.9] and 47 [26.9] letters), and 24-month mean VA changes were similar for nonsubfoveal (−7.6 and −6.2) and subfoveal (−7.9 and −6.5) subgroups. Progression to subfoveal GA occurred in 16.7% of nonsubfoveal study eyes in the GA:GA cohort and 12.5% in the GA:nAMD cohort. More new-onset study-eye nAMD was observed in the GA:nAMD (21.6%) versus GA:GA (8.2%) cohorts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Foveal progression in U.S. Medicare Advantage claims
“At index, 4,781 (50.3%) individuals had GA without SFI and 4,697 (49.4%) had GA with SFI. Among individuals with GA without SFI at index, 479 (10.2%) progressed to GA with SFI during the 12-month follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Significant predictors of progression to GA with SFI were wet AMD at baseline (HR [CI] = 5.70 [4.63-6.99], P < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity loss over 4 years by baseline acuity and lesion proximity to the fovea
“We included 1351 eyes from 994 participants, including 594 eyes from 464 participants with 4-year BCVA follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, 483 eyes that met both criteria of baseline BCVA ≥ 40 letters and GA lesions involving or within 1 mm of the foveal center showed significant BCVA loss over 4 years (mean change = −11.33 letters [95% confidence interval = −12.80 to −9.84]), with faster GA progression associated with larger BCVA loss (P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity loss over 2 years in the lampalizumab trials
Visual acuity loss and progression to neovascular AMD in bilateral geographic atrophy in U.K. practice
“In the worse-seeing eye, 40.1% lost ≥10 letters in 2.4 years. Among patients with baseline and 24-month VA measurements, mean VA decline was 6.1 letters in the worse-seeing eye (n = 413) and 12.4 letters in the better-seeing eye (n = 414). The rate of progression to CNV in either eye was 7.4% per patient-year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression to neovascular AMD after incident geographic atrophy in AREDS2
Progression from unilateral to bilateral geographic atrophy
Mortality: total area of geographic atrophy and all-cause mortality
“During a median follow-up of 6.8 years, 48 (23.0%) participants with GA died. In adjusted models, accounting for age, sex, and health status, participants with total GA area in the highest quartile had a significantly increased risk of all-cause mortality compared to those with total GA area in the lowest quartile (hazard ratio [HR], 3.42; 95% confidence interval [CI], 1.32-8.86; P = 0.011). GA effective radius growth rate, bilateral disease, and the presence of foveal center involvement were not significantly associated with mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: late AMD and all-cause and cardiovascular mortality (geographic atrophy and neovascular AMD combined)
“Late AMD was associated with elevated rates of all-cause (nine studies, hazard ratio (HR) 1.20, 95% confidence interval, CI, 1.02-1.41) and cardiovascular mortality (six studies, HR 1.46, 95% CI 1.13-1.98), but early AMD was not (all-cause mortality, 10 studies, HR 1.06, 95% CI 0.98-1.14; cardiovascular mortality, five studies, HR 1.12, 95% CI 0.96-1.31).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of all-cause mortality and cardiovascular mortality associated with early AMD were 1.08 (1.00-1.18) and 1.05 (0.89-1.24), and the associations with late AMD were 1.23 (1.11-1.36) and 1.28 (1.04-1.57), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote